HIV REVERSE TRANSCRIPTASE VACCINE

Abstract: A synthetic vaccine comprises a recombinant vaccine vector that incorporates a nucleotide sequence capable of being expressed as all or part of an HIV reverse transcriptase. The vector is combined with all or part of a purified HIV reverse transcriptase in an adjuvant. The vaccine vectors include poxvirus, herpes virus, and adenovirus. The synthetic vaccine applies particularly to the augmentation of immune responses in HIV-infected asymptomatic, immunosuppressed, or immunodeficient animals or humans.

Description: HIV REVERSE TRANSCRIPTASE VACCINE BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to synthetic vaccines for immunizing against human immunodeficiency virus (HIV) . More particularly, the invention relates to recombinant vaccine vector-encoded HIV reverse transcriptase (RT) , combined with at least one booster inoculation of purified HIV RT in an adjuvant. 2. Related Art HIV, a human retrovirus, causes both acquired immune deficiency syndrome (AIDS) and acquired immune deficiency related complex (ARC) . During the past decade, this virus has infected 5 to 10 million people worldwide and caused over 200,000 deaths due to complications arising from AIDS. Many attempts have been made to immunize animals and humans with prototype vaccines, but none of them have been particularly effective in protecting against or moderating the onset of the disease. Development of an effective AIDS vaccine has been hampered by severe problems. Most present research strategy produces vaccines based on the glycoprotein envelope of HIV. However, the amino acid sequence of the glycoprotein envelope, gpl20, exhibits a high degree of variability among virus particles obtained from different patients, or even from the same patient at different times. These ongoing mutations in the virus envelope lead to ineffective vaccines that fail to provide an immune response to the constantly changing HIV. Certain criteria are necessary for an effective vaccine against HIV: (1) an HIV portion that elicits the most powerful natural immune response; (2) an HIV portion whose amino acid sequence is reasonably conserved; (3) protection against any HIV isolate; (4) a high enough level of immune response amplification to overcome HIV; (5) an immunogen that produces humoral and cell-mediated immunity; and (6) an immunogen that excludes sites which might induce deleterious side effects. Therefore, a need continues to exist for a vaccine that provides both protective immunity to HIV-negative individuals and effective therapy to HIV-positive asymptomatic individuals. The present invention provides just such a vaccine using HIV RT to induce both a humoral and a cytotoxic T-σell response. SUMHARY OF THE INVENTION In one aspect, this invention provides a synthetic vaccine. It comprises a recombinant vaccine vector that incorporates a nuσleotide sequence capable of being expressed as all or part of an HIV RT. The vector is combined with all or part of a purified HIV RT in an adjuvant. Both the HIV RT expressed by the recombinant vector and the purified HIV RT in the adjuvant can be a 66 Da subtthit Of the HlV RT. In another aspect, the present invention provides a method for producing an immune response in an animal or human by the step of administering a synthetic vaccine, as broadly described above. The present invention applies particularly to the augmentation of immune responses in HIV-infected asymptomatic, immunosuppressed, or immunodeficient animals or humans. In one important aspect, a synthetic vaccine is used in the treatment of HIV-infeσted asymptomatic, immunosuppressed, or immunodeficient animals or humans. The synthetic vaccine is made up of two parts: (1) a recombinant vaccine vector that incorporates a nucleotide sequence capable of being expressed as all or part of an HIV RT, and (2) at least one booster inoculation of purified HIV RT in adjuvant to enhance the immune response of the animal or human. BRIEF DESCRIPTION OF THE FIGURES FIG. 1 schematically represents the construction of the vaccinia recombination vector; FIG. 2 shows a Western blot of W:RT-infected cell lysates } FIGS. 3a and 3b are Western blots showing a time course of expression study to detect HIV RT; FIG.4 shows an antibody response in W:RT-infected mice and rabbits; FIG. 5 shows the longitudinal titers of anti-RT antibodies in rabbits; FIG. 6 shows antibody response against HIV RT in African green monkeysJ FIG. 7 is a graph showing the results of an assay to determine the titer of the anti-RT antibody in African green monkey sera; and FIG. 8 is a graph showing the results of an assay to determine the titer of RTI antibodies in vaccinated African green monkeys. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a synthetic vaccine containing HIV RT, which acts as an immunotherapeutiσ or immunopreventive agent for the treatment of HIV infected individuals. The approach is to produce a synthetic vaccine that consists of two parts. The first part is in the form of a recombinant vaccine vector, such as a recombinant vaccinia virus (rW) . The rW was constructed by inserting a nucleotide sequence from the HIV viral genome into a wild-type vaccinia virus (W) . That portion of the HIV genome thus becomes expressed by the recombinant virus. Specifically, the invention inserts a nucleotide sequence that encodes the HIV RT gene into W, so that the rW functions as a vaccine when inoculated into humans. Although this invention is primarily described with reference to W as the vaccine vector, other vaccine vectors (such as other poxviruses, herpes virus, adenovirus, or bacteria) may be used. The second part of the vaccine, consisting of purified HIV RT in adjuvant, provides a booster effect. HIV RT is a suitable target for immunopreventative measures against HIV, as shown by the following: (1) a correlation between progression to acute AIDS and the loss of antibodies against HIV RT (Laurence, et al., Science , 2_i_>ϊ1501-1504, 1987), (2) the presence of cytotoxic T lymphocytes directed against HIV RT in infected individuals (Walker, et al., Science , 240:64-66, 1988), and (3) the expression of the HIV RT antigen on CD4- positive cells in the peripheral circulation of HIV- seropositive individuals. See U.S. Patent No. 4,904,581. By immunizingHIV-infectedasymptomatic, immunosuppressed, or immunodeficient individuals and periodically boosting with pure HIV RT, the viral spread and progression to AIDS could be effectively controlled. It is also conceivable that, even if an anti-RT vaccination of HIV-negative individuals does not protect them from HIV infection, it could, for the same reasons, at least control the disease. The use of W as a live vaccine vector for the HIV RT gene (1) facilitates a humoral and cellular immune response to HIV RT and (2) provides prophylactic protection against HIV infection or assists in therapy. The current knowledge of the genetic structure of HIV includes ten genes that are bounded by long terminal repeats (LTRs) . LTRs are sequences at both ends of the HIV DNA that do not code for any protein. Instead, they initiate the expression of viral proteins. Only three of the HIV genes, gag, pol r and env, encode components of virus particles. The other HIV genes regulate the expression of these three genes. The amino acid horaology between at least 14 different HIV isolates has shown the pol gene of HIV to be the most highly conserved (Myers, et al., eds., Human Retroviruεes and AIDS, 1990, Los Alamos National Laboratory) . The amino acid homology in the pol gene was 81% between isolates, compared with the gag gene, which was 71%, and the env gene, which was 44%. When the region encoding the RT polypeptide in pol is compared, an 83% homology is observed. The conserved nature of RT supports its use as a vaccine, because, unlike the envelope gene, the degree of antigenic drift is minimal. Previous efforts have focused on expression of the entire pol open reading frame in rW infected cells. This strategy required proteolytiσ processing of the pol polyprotein into protease, HIV RT, and integrase in order to obtain native HIV RT (Farmerie, et al.. Science , 216:305-308,1987). The native HIV RT underwent further prσteolytiσ processing by the HIV protease. The HIV was partially cut an additional time, a small sequence at the c-terminus removed, and a heterodimer, containing 66 and 51 kDa stibunits, formed that had common N termini. This further cleavage of the HIV RT may affect the characteristics of the enzyme. In addition, this essential proteolysis is inefficient and results in low levels of native HIV RT in rW infected cells. Animals infected with these initial rW constructs developed low or undeteσtable immune responses to pol gene products. To eliminate the need for proteolysis leading to the heterodimer, a different set of rWs were constructed, using only the coding sequences for native HIV RT. This was accomplished using specially designed oligonuσleotide primers and the polymerase chain reaction (PCR) . The method allowed isolation of a segment of the pol region that encoded only a 66 kDa subunit of those amino acids comprising the native HIV RT. The resulting rW generated high levels of HIV RT in infected cells and significant antibody titers in vaccinated mice, rabbits, and monkeys. HIV-infeσted individuals have been shown to present RT antigens on T-cells at early stages of HIV infection. A monoclonal antibody against HIV RT specifically binds to CD4-positive cells in the peripheral circulation of HIV- seropositive individuals. See U.S. Patent No. 4,904,581. If these RT-presenting cells represent the HIV-infected cell population, a strong cytotoxic T-σell response against HIV RT could protect an individual by clearing infected cells before the virus has a chance to spread. HIV-infected individuals are known, to develop antibodies against HIV RT without this enzyme being presented to the immune system by viral particles. HIV is unique among retroviruses, including HTLV-I and HTLV-II, in its ability to induce anti-RT antibodies. Next to the envelope protein gp4l, the most frequently recognized viral antigen in seropositive individuals are the p51, p66 proteins which comprise RT. Furthermore, a correlation has been shown between the loss of RT-inhibiting (RTI) antibody and worsening clinical disease (Laurence, et al.. Science , 223.:1501-1504, 1987; Advani, et al. , J. Clinical Microbiology, 21-'1453-1455, 1989) . The loss of antibodies capable of inhibiting HIV RT activity occurs, even though RT-binding antibodies are present (DeVico, et al., AIDS Res. Hum. Retroviruses, 4_:17-21, 1988). The presence or absence of RTI antibody has been proposed as a marker of advanced AIDS. Therefore, a vaccine that induces RTI antibodies in an individual, with the use of a boost regimen that keeps RTI antibody levels high, could prevent the progression of AIDS. Because T-σell-mediated cytotoxicity is an important factor in the control of infections including HIV, the presence of RT-specific cytotoxic T-lymphoσytes (CTL) is an important observation in infected individuals. Several groups have characterized the presence of RT-specific CTLs in HIV-infected humans, and recent reports have identified RT-specific CTL epitopes (Wεllker, et al., Science , 240:64- 66,1988; Walker, et al., Proc. Natl . Acad. Sci . USA , £_£:9514-9518, i989; Hosmalin, et al., Proc. Natl . Acad. Sci . USA , 87:2344-2348, 1990). The observed degree of difficulty in culturing HIV from the peripheral blood mononuclear lymphocytes of seropositive individuals has been correlated with the serum level of RTI antibodies (Sano, et al., J. Clin . Microbiol . , 23.-2415-2417, 1987). This observation suggests that the presence of high RTI antibody levels may decrease the replication of virus in infected individuals. If that is correct, it supports the argument for continued immunization against RT in infected individuals. Human subjects responded marginally to primary inoculation with vaccines (VAC/ENV) that consisted of vaccinia recombinant virus expressing the HIV envelope glycoprotein, gpl60. However, such subjects demonstrated a significant boost in humoral, as well as cell-mediated immunity, following a boost with purified envelope glycoprotein (Hu, et al., Abstracts from VI International Conference on AIDS, Th.A.343, 1990). Individuals with clinical and laboratory evidence of prior smallpox immunization demonstrated a low primary response to VAC/ENV but a subsequent boost effect with purified protein was observed. Additionally, in a murine system the combination of first priming with VAC/ENV, followed by the purified protein boost, resulted in a greater humoral immune response than either of the two regimens by themselves (Cooney, et al., Abstracts from VI International Conference on AIDS, Th.A.333, 1990). The studies of Hu, et al. and Cooney, et al. above show that a successful immunization for HIV is possible by first priming with a vaccinia-HIV construct expressing gpl60, and then following with ύ boost of the purified gpl60 in adjuvant. In an early and promising Phase I vaccine trial, ARC and AIDS patients were immunized against an HIV preparation to prevent worsening clinical status (Piσard, et al.. Lancet, 336:179, 1990). The vaccine consisted of vac- pol, gag, and env constructs, as well as immunogenic synthetic peptides from the same proteins. Autologous cells were isolated from each individual, infected with the vaccinia constructs in vitro, fixed with paraformaldehyde, and re-innoσulated into the patient. In 19 vaccinated patients no opportunistic infection episodes were observed, and weight was maintained out to 9 months post-vaccination. Additionally, the absolute levels of CD4 cells stabilized or increased significantly in the vaccinated individuals as compared with a control group. These encouraging results indicate that therapeutic vaccination of seropositive individuals might be an effective therapy. Vaccination with the vaccinia σonstruct-infected cells may be an important part of the immunization protocol, because these cells are expressing HIV epitopes in association with class I MHC determinants. This is essential for the induction of CD8 positive cytotoxic cells. Significantly, soluble proteins found in conventional vaccines do not efficiently generate these types of effector cells. The administration of the rW is generally by means of scratching the skin and application of infectious rW. A localized lesion develops as a result of infection of cells at the site of administration. Non-sterile conditions are often acceptable. For the purified HIV RT, administration is slightly more complex. The HIV RT can be prepared as an injectable, either as a liquid solution or suspension; a solid form suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The HIV RT can be mixed with excipients which are pharmaceutically acceptable and compatible. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, the HIV RT can be combined with minor amounts of auxiliary substances such as wetting or emulsifying agents, or pH buffering agents. The invention encompasses the use of the purified HIV RT in adjuvant as a booster inoculation to enhance the immune response. Normally, the adjuvant and the HIV RT are mixed prior to presentation to the immune system, or presented separately, but into the same site of the animal or human being immunized. Adjuvants can be loosely divided into several groups based on their composition. These groups include water-ln-oil emulsion adjuvants, such as complete Freund's adjuvant, in which living or dead mycobacteria arβi suspended. The intense, chronic inflammation around the deposits of emulsion of this adjuvant precludes it use in man. However, incomplete Freund's adjuvant which has an emulsion without mycobacteria is less irritating and has been used clinically. Other groups of adjuvants include mineral salts (for example, AlKfSO j , AlNa(S0 4 ) 2 , A1NH 4 (S0 4 ), silica, alum, Al(OH) 3 , Ca 3 (P0 4 ) j , kaolin, and carbon) , polynucleotides (for example, poly IC and poly AU acids), and certain natural substances (for example, wax D from Mycobacterium tuberculosis, as well as substances found in Corynebacterium parvum, Bordetella Pertussis, and members of the genus Brucella) . Another substance useful as an adjuvant is Quil A, a crude mixture of saponins that has detergent-like properties. The purified HIV RT in adjuvant is conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration includesuppositories, intranasal aerosols, and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glyσols or triglyσerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%- 2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and contain 10%-95% of active ingredient, preferably 25%-70%. The HIV RT may be formulated into neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups) which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, and ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine, and the like. The HIV RT in adjuvant is administered in a manner compatabile with the dosage formulation, and in such amount as to be immunoeffective either as a therapeutic or preventitive. The quantity to be administered depends on the animal or human to be treated, capacity of the individual's immune system to produce antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only, and are not intended to limit the scope of the invention. EXAMPLE 1 Construction Of A Vaccinia Recombination Vector According to FIG. 1, the top line represents the genome of HIV-1 and the boxes below the line signify the known genes. RF1, RF2, and RF3 in FIG. 1 indicate the three open reading frames. Each gene is aligned with one of these open reading frames. The pol gene consists of a polyprotein encoding protease (prot) , reverse transσriptase (RT) , and integrase (INT) . The RT portion of the pol gene was isolated by PCR. The PCR primers shown in FIG. 1 are aligned with the pBHIO sequence. The PCR fragment produced was digested with Nco I and ligated to pUCK-19. The pUCK-19 vector had been digested with Asp718, treated with Klenow, and digested finally with Nco I. The resulting clone, pUCK-RT, was used to generate the pW3-RT vaccinia recombination vector. The remaining part of the example is a detailed description of the construction of the vaccinia recombination vector. A full-length infectious clone of HIV-1, pBHIO (Ratner, et al., Nature, 313:277-284. 1985), was used as the source of cloned viral DNA. Oligonucleotide primers were designed such that after PCR, an ATG start codon and a TAG stop codon are at the beginning and end, respectively, of the HIV RT coding region. The oligonucleotide primers and the strategy used in the remainder of the recombinant DNA phase of this project are shown in FIG. 1. The 5 1 primer was also designed to have a speσfic restriction enzyme recognition site (Nco I) at the 5' end to facilitate recombinant DNA manipulations. The amino terminal amino acid of native HIV RT is a proline at nucleotide position 1909. The PCR- derived HIV RT required the addition of methionine and valine at the amino terminal end to allow translational initiation at the Nco I restriction site (see FIG. 1) . PCR was performed using the two primers shown in FIG. 1 in a lOOμl reaction volume containing containing lO M Tris-HCl (pH 8.3), 50mM KCl, 1.5mM MgCl 2 , 0.1% gelatin, 100 pmoles of each primer, and 1 ng of pBHIO. The reaction mixture was subjected to thermal cycling as follows: 94"C for 1.0 min. ,* 45*C for 1.0 min. ; and 72'C for 3 min. This cycle was repeated for 30 times and the amplification was terminated with the final 72*C incubation held for 10 minutes. The 1691 base pair PCR fragment was purified by preparative agarose gel electrophoresis, digested with Nco I, and inserted between the Nco I site and Klenow- treated Asp 718 site of pUCK-19. pUCK-19 is a vector specially engineered for insertion of eukaryotiσ genes. It was designed to include a consensus eukaryotiσ ribosome binding site, Kozak sequence GCCACCATGG (Kozak, J. Mol . Biol . , 196:947-950. 1987). pUCK-19 was constructed by inserting a synthetic oligonucleotide containing the sequences shown in FIG. 1 between the Bam HI and Kpn I sites of pUC19 using standard procedures (Maniatis, et al., Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982). The validity of the resulting pUCK-RT clone was verified by determination of the DNA sequence at the 5* and 3' ends of the HIV RT gene in this plasmid. The DNA sequence confirmed the presence of the ATG start codon and the TAG stop codon in the proper reading frame. Furthermore, the 200bp of HIV RT coding sequences that were determined at the 5' and 3' ends of the gene matched exactly the published DNA sequence of the pBHIO clone (Ratner, et al. , Nature, 112:277-284, 1985). The pUCK-RT clone was then digested with Bam HI and Sac I and the HIV RT fragment was inserted into the same sites of pW3 (see FIG. 1) . pW3 is a vaccinia recombination vector developed by Dr. Denis Hruby at Oregon State University, Corvallis, OR (Thomas, et al., Science , 212:1641-1643, 1986). EXAHPLE 2 Marker Transfer Of pW3-RT Into Wild-type (wt) W Introduction of the HIV RT gene into the W genome was accomplished by cotransfeσtion of pW3-RT and wtW DNA into Ltk" cells obtained from Dr. Denis Hruby at Oregon State University, Corvallis, OR. Ltk " cells were seeded onto 100mm culture dishes at approximately 50% confluency on day one. On day two the cells were infected at a multiplicity of infection (MOI) of 0.05 with wtW. The infection was allowed to proceed for exactly 3 hours before the additon of the DNA. DNA for transfeσtiσn was prepared using the Lipofectin reagent according to the manufacturer's instructions (Bethesda Research Laboratories) . Twenty μg of pW3-RT plasmid DNA was mixed with one μg of wtW DNA and used for the cotransfeetion step. After 24 hours, the infected cells were harvested by scraping the cell monolayer, and a crude W stock was prepared by three consecutive freeze thaw cycles, which lysed the infected cells. Further amplification of the W occurred in mouse Ltk " cells grown in BUdR (25μg/ml) containing medium. These mouse Ltk" cells were selected for those vaccinia viruses that had lost the wt thymidine kinase (tk) gene as a result of recombination with the tk sequences that flank the HIV RT sequences in pW3-RT (see FIG. 1) . This was accomplished by infecting BudR-selected Ltk " cells with the crude stock at an MOI of 0.2 and by making a second crude stock by lysing the cells at 72 hours post-infection. Viruses from the BudR selection were plated and screened for HIV RT gene sequences by plaque hybridization. Briefly, lOOmm dishes of confluent BSC40 cells (ATCC, Rockville, MD) were infected with 500 pla ue-forming units of W, and the infection was allowed to proceed for 36 hours. The addition to the eight mis of culture medium of five mis of 1% neutral red in PBS for three hours at 30"C stained the cells and allowed visualization of the plagues. The monolayers with vaccinia plaques were transfered to 87mm nitrocellulose filters by first draining the medium, then placing the filters directly onto the cells. The filters were lifted from the plates and placed cell side up on PBS-soaked filter paper. A replicate filter was made by placing a second nitrocellulose filter against the first filter. The original filter was stored at 70 β C to preserve the viruses in each plaque, while the replica was screened for positive plaques using an approach identical to bacteriophage lambda plaque hybridization (Maniatis, et al., .Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, K.Y., 1982). The plaque hybridization procedure used as a probe, "P- labeled DNA, generated by random-priming DNA from the PCR reaction described above. Several positive plaques were grown and screened for the correct genome structure using restriction mapping procedures of DNA isolated from partially purified W. Of the several W:RT recombinant clones resulting from this analysis, W:RT-3 and W:RT- 24 were selected. A sample of the vaccinia recombination vector herein designated W:RT-3 has been deposited with the American Type Culture Collection (ATCC) at 12301 Parklawn Drive, Rockville, MD 20852 USA and has been given ATCC accession number VR 2289. EXAMPLE Molecular Analysis Of Recombinant Vaccinia Infected Cells The African green monkey cell line BSC40 was used for all infections. FIG. 2 shows a Western blot of W:RT infected cell lysates using human anti-HIV sera, Human High Positive Sera (Epitope, Inc.), as the detecting antibody. HIV RT is expressed in the W:RT infected cells. The Western Blot is performed on protein extracts from vaccinia-infected or mock infected cells. The polyacrylamide gel electrophoresis and electroblotting was performed using standard procedures. Lanes 1-3 are W:RT isolates #24 and #3, lane 4 is wild-type vaccinia virus (W:wt) ; and lane 5 is mock infected BSC40 cells. A 66 kDa band specific to the W:RT clones is clearly evident. FIGS. 3a and 3b are identical Western blots showing a time course of expression study of RT in W:RT-infected cells using two different anti-RT monoclonal antibodies (MAb) to detect HIV RT. Lane 1 is a molecular weight marker; lane 2 is mock infected BSC40 cells; lanes 3-5 are pre- infection, T 0 ; lanes 6-8 are two hours post-infection, T 2 ; lanes 9-11 are seven hours post-infection, T 7 ; lanes 12- 14 are 24 hours post-infection, T 24 ; and lane 15 is purified HIV. The lane order within each time point is W:wt, W:RT3, and W:RT24. The Western blot in FIG. 3a was developed using 1C11 MAb (Epitope, Inc.) and in FIG. 3b commercially available anti-RT MAb (Cellular Products, Inc.) . Both MAbs showed specific and strong reaction with a 66 kDa band that aligns exactly with the native p66 protein from purified HIV (lane 15) . It should be noted that W:RT does not express the HIV protease necessary for processing of HIV RT to the 51 kDa form. EZAMPLE 4 Purification Of HIV RT For Boosts HIV RT was purified from W:RT-infected HeLa cells using a modification of a published protocol (Flexner, et al., Virology, X6£:339-349, 1988). Briefly, 5 x 10 9 HeLa cells grown in suspension were infected with 5 x 10 10 pfu of W:RT-3 and were allowed to grow for 24 hours. The cells were lysed in 25 mis of a hypotonic buffer, and the nuclei pelleted by centrifugation. The supernatant measured 25ml and contained the bulk of the HIV RT. The lysate was adjusted to 75 M NaCl, 50mM Tris-HCl (pH 8.0), ImM DTT, and 0.01% NP40 (Buffer A) and applied to a 2.5 x 12.5σm DEAE Sepharose (Pharmacia, Inc.) column equilibrated with Buffer A. Unbound protein was eluted with 100ml of Buffer A. Bound proteins were eluted with a two-step gradient of 150 and 3Q0mM NaCl. Column fractions were analyzed by Western blot for HIV RT using the 1C11 anti-RT mAb (Epitope, Inc.) as the detecting antibody. The bulk of the HIV RT was in the flow through fractions and the 50ml that contained the HIV RT were loaded onto the same sized column containing phosphocellulose (Whatman, Inc.) equilibrated with buffer A. Unbound protein was eluted with 20ml of buffer A, and a 200ml NaCl gradient from 75mM to 300mM was used to elute the HIV RT that had bound to the column. The collected fractions were analyzed for HIV RT on Western blots and for total protein on Coomassie blue-stained polyacrylamide gels. The fractions containing pure RT were pooled and concentrated using a Centriprep 30 concentrator (Amicoh, Inc.). The protein concentration of the concentrated preparation was 133 μg/ml, as determined using the BCA Protein Assay Reagent (Pierce) . EΣAMPLE 5 Xβaunization Of Mice And Rabbits The presence of a yellow, crusty scab at the site of inoculation, approximately five days post-immunization, indicated a successful vaccinia infection in all animals challenged. In addition, all immunized animals demonstrated a positive Western blot response against vaccinia virus proteins. Western blot anaylsis of sera utilizing commercially available HIV-1 viral lysate Western blot strips (EpiBlot™, Epitope, Inc.) indicated that anti-p66 and p51 antibodies were generated in 4/4 vacσinia-RT immunized rabbits as early as 14 days post- inoculation (FIG. 4) . The Western blots were developed according to the manufacturer's instructions. Four rabbits (CA, #93, #94, #95) were infected with W:RT-3 and bleeds were taken at days 0, 7, 14, 35, and 42. These sera were used on the strips at the top of FIG. 4. Hu high- in FIG. 4 is human high postive anti-HIV sera from Epitope, Inc. In FIG. 4, NRS is normal rabbit sera and anti RT mAb is the 1C11 monoclonal antibody. The bottom half of FIG. 4 shows the antibody response in the same four rabbits following boost with 50μg of purified RT and the entire vaccination regimen in mice. The rabbit sera used are from days 7 and 14 post-boost. Four mice were infected with W:RT-3 and two control mice with W:wt. The sera used were from days 14 and 32 post-infection and day 8 post-boost with 50μg of purified RT. NMS in FIG. 4 is normal mouse sera. Sera from all of the W:RT-infected mice developed a faint p66 band, at 14 days post- inoculation. In contrast, sera from mice immunized with a wild-type vaccinia preparation and normal mouse sera did not develop either p66 or p51 bands on the blots (FIG. 4) . At 28 days post-inoculation 3 of 4 rabbits were p66 and p51 seropositive. One rabbit designated CA. , which was positive at day 14, reverted to a seronegative status at day 42. All four vacσinia-RT mice continued to be seropositive for p66, as well as for p51 at 32 days post- inoculation. The three rabbits seropositive at day 28 continued to test positive against HIV RT (p66, p51) at both 35, 42, and 72 days post-inoculation. The mice and rabbits were boosted with purified HIV RT in Complete Freund's adjuvant and both groups of animals responded by generating high titered antisera against HIV RT. The boosted mice and rabbits were used to generate a panel of anti-RT monoclonal antibodies and high titered antisera, respectively. Sera from two of the boosted rabbits were collected weekly for several months and were analyzed on EpiBlot™ strips as shown in FIG. 5. EXAMPLE 6 Immunization Of African Green Monkeys W:RT-3 was Used to induce a humoral and cellular immune response against HIV-RT in African green monkeys (AGM) . Each AGM was inoculated by skin scarification with lO'PFU of vaccinia virus. Six animals were infected with W:RT and two with W:wt. As shown in FIG. 6, animals infected with the W:RT specifically induced antibodies against HIV-RT, as determined by running 0, 3, 4, and 5 week post- infection sera on HIV-1 Western blot strips. In FIG. 6, the top two sets of blots show the anti-RT response in monkeys following infection with W:wt or W:RT-3. Each set of 4 strips is from a single animal at days 0, 21, 28, and 35 days post-infection. The bottom panel shows the boost response to RT in the vaccinated monkeys. Each set of three strips is from a single animal and represents sera from 0, 7, and 17 days post-boost. Animals J261 and J571 were not boosted since they were the W:wt control animals. The humoral anti-RT response was confirmed by running the sera against Western blot strips generated from either W:wt or W:RT infected cell lysates. Although the anti-RT reactivity is weak, a boost with purified RT significantly enhanced this response as was seen in both mice and rabbits. Four months after infection with W:RT-3 the boost was administered using lOOμg of purified HIV RT in a threonyl-MDP adjuvant (Syntex) . Purified HIV RT was dialyzed against PBS (pH 7.2) without Mg ** and Ca* * and the concentration was determined to be 133μg/ml. The threonyl-MDP was administered at lOOμg/kg body weight. The adjuvant was mixed with an equal volume of SAF carrier and administered at lOOμg/kg body weight and then injected intramuscularly. Sera were obtained at 7, 17, 21, and 28 days post-boost and analyzed as in FIG. 4 on EpiBlot™ HIV- 1 Western blot strips. The results are shown in the bottom panel of FIG. 6. To determine the titer of the anti-RT antibody in the AGM sera, an RT-enzyme-1inked immunoabsorbent assay (ELISA) was performed using serial dilutions of the sera from the 28 day bleeds. This assay was performed by coating the wells of a 96-well miσrotiter plate with lOOng of purified HIV RT and reacting the wells with serial two-fold dilutions of the antisera. RT- specific antibody was detected using peroxidase conjugated to antibody that recognizes AGM antibodies. As seen in FIG. 1 , the anti-RT titer of the animals exceeded a 10*- fold dilution at two weeks post-boost. Using an enzyme- linked immunosorbent assay (ELISA) format, the antibody titer was measured by determining the dilution the sera could withstand and still have reactivity to purified RT. The titer is represented as the dilution factor of each sera that resulted in a signal two-times background. Each line represents one animal. Animal J261 and J571 were the W:wt control animals. The presence of antibodies that inhibit the enzymatic actvity of HIV RT are of clinical relevance. To determine the titer of RT-inhibitory (RTI) antibodies that this vaccine can generate in AGM, an enzymatic assay was developed, and serial dilutions of the AGM antisera were tested for the ability to inhibit HIV RT. As shown in FIG. 8, the titer of RTI antibodies in four of the AGMs exceeded a 12,000 dilution. The assay was conducted using detergent disrupted HIV-1 from actively infected cells and a standard HIV-1 RT assay (Goff, et al., J. Virol . , 18.:239-248, 1981). This assay was performed using HIV strain 111b from Hut78-infected cells cultured at Epitope. A standard HIV reverse transcriptase assay (Technicmes in HIV Research. Eds. A. Aldovini and, B.D. Walker, Stockton Press, 1990, and Goff et al., J. Virol . , 8.:239-248, 1981) was modified to incorporate a preincubation with monkey sera as follows. Sera were diluted in PBS and 5μl of each dilution was incubated with 5μl of detergent-disrupted cell-free supernatant from the Hut78-infected cultures. The detergent disruption was performed by making the HIV containing culture medium 0.05% NP40. The incubation of virus with sera was performed at 4°C for 30 minutes. The 10μl samples were then added to a 50μl RT reaction mixture and assayed as described in the above cited assays. Data are represented as that dilution at which there is 20% inaσtivation of the RT activity when compared to negative control values. The two wild-type vaccinia control monkeys are J261 and J571 and are slhown as having an inhibition titer of 25. Since the lowest dilution measured was a 25-fold dilution and these two sera allowed 100% RT activity at this dilution, their actual inhibition titer is probably much lower. The cell mediated response of the immunized animals to both HIV RT and W was assessed by stimulating peripheral blood lymphocytes with the antigen and measuring tritiated thymidine uptake at six days. As shown in Table 1 below, two of the six RT-vacσina ed animals had lymphocyte stimulation indices (LSI) that exceeded five. In Table 1, the numbers under the headings of No Antigen and [RT] represent the counts per minute of tritriated thymidine incorporated into cellular DNA. Although only two of six animals demonstrated cellular proliferation in the presence of RT, it is clear that the vaccine described herein is fully capable of eliciting an RT-specifiσ cellular response. Fresh whole blood from each monkey was used as the source of peripheral blood lymphocytes used in the assay results shown in Table 1. The amount of RT in each well is shown at the top of Table 1. The lymphocytes stimulation was determined by measuring tritriated thymidine uptake at six days. The degree of stimulation is shown as the LSI and is the ratio of the incorporated counts from the antigen- containing wells divided by the counts from the no antigen wells. Table 1. RT- specific Lymphocyte Proli eration in Vaccinated African Green Monkeys EXAMPLE 7 Construction Of An Adenov rus Recombinant Vector The starting virus for the adenovirus construct is adenoviru type 5 deletion mutant dl 327 that lacks the Xba fragment fro 78.5 map units to 84.7 map units in early region 3 (Cutt, e al . , J. Virol., 61:543, 1987). This deletion mutant allow the insertion of DNA without exceeding the amount of DNA tha can be included in the virus particle. The removal of the E region also prevents production of a virus protein that complexes with the major histocompatibility heavy chain protein and reduces the eel1-mediated immune response to th virus. The Bam fragment from 60 map units to the right han end of the viral DNA is cloned in plasmid. The plasmid DN is cut downstream of the E3 promoter with a suitable restriction enzyme, and the HIV RT gene inserted in place o the original E3 gene, under the control of the natural ET E3 promoter. The resulting plasmid containing the HIV RT gene in the 60 to 100 map unit fragment of dl 327 is cut with the appropriate restriction enzyme to separate viral and plasmid DNA, and transfected into cells together with the overlapping EσoRl A fragment (0 to 76 map units) of wild type virus. Recombination between the two overlapping DNA fragments will reconstitute viable adenovirus in which the E3 gene is replaced by the HIV RT gene. The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made without departing from the spirit or scope of the invention.

Claims: CLAIM8 1. A synthetic vaccine, for immunizing an animal or human against HIV, which comprises: (a) a recombinant vaccine vector, the genome of which comprises, in a non-essential region, a nucleotide sequence capable of being expressed as all or part of an HIV reverse transcriptase; and (b) all or part of a purified HIV reverse transcriptase in an adjuvant. 2. The synthetic vaccine according to claim 1, wherein the recombinant vaccine vector is a virus. 3. The synthetic vaccine according to claim 2, wherein the virus is selected from the group consisting of a poxvirus, a herpes virus, and an adenovirus. 4. The synthetic vaccine according to claim 3, wherein the poxvirus is vaccinia virus. 5. The synthetic vaccine according to claim 1, wherein the nucleotide sequence is expressed as a 66 kDa subunit of the HIV reverse transcriptase. 6. The synthetic vaccine according to claim 5, wherein the recombinant vaccine vector is a virus. 7. The synthetic vaccine according to claim 6, wherein the virus is selected from the group consisting of a poxvirus, a herpes virus, and an adenovirus. 8. The synthetic vaccine according to claim 7, wherein the poxvirus is vaccinia virus. 9. The synthetic vaccine according to claim 1, wherein the purified HIV reverse transcriptase is a 66 kDa subunit of the HIV reverse transcriptase. 10. The synthetic vaccine according to claim 9, wherein the recombinant vaccine vector is a virus. 11. The synthetic vaccine according to claim 10, wherein the virus is selected from the group consisting of a poxvirus, a herpes virus, and an adenovirus. 12. The synthetic vaccine according to claim 11, wherein the poxvirus is vaccinia virus. 13. A method for producing an immune response in an animal or human, particularly HIV-infected asymptomatic, immunosuppressed, or immunodeficient animals orhumans, which comprises administering to the animal or human a priming inoculation of the recombinant vaccine vector as in any of claims 1-8 or 10-12, followed by a booster inoculation of all or part of the purified HIV reverse transcriptase in the adjuvant, effective in enhancing the immune response of the animal or human to the HIV reverse transcriptase. 14. The method according to claim 13, wherein the purified HIV reverse transcriptase is a 66 kDa subunit of the HIV reverse transcriptase. 15. A synthetic vaccine for use in the treatment of HIV-infected asymptomatic, immunosuppressed, or immunodeficient animals or humans, which comprises administering a priming inoculation of the recombinant vaccine vector as in any of claims 1- 8, or 10-12 followed by a booster inoculation of all or part of the purified HIV reverse transcriptase in the adjuvant, effective in enhancing the immune response of the animal or human to the HIV reverse transcriptase. 16. The vaccine according to claim 15, wherein the purified HIV reverse transcriptase is a 66 kDa subunit of the HIV reverse transcriptase.

Inventors: BESTWICK RICHARD K, FERRO ADOLPH J, BESTWICK, RICHARD, K., FERRO, ADOLPH, J.
Applicants: EPITOPE INC, EPITOPE, INC.
Application year: 1991
Main classification: A61K39
IPC codes: A61K39, C07K14, C12N15